Associated Papers
Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.
Jones RL et al.
Nature Communications, 2026
IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications.
Choate KA et al.
Biology, 2024
Diagnostics of IDH1/2 Mutations in Intracranial Chondroid Tumors: Comparison of Molecular Genetic Methods and Immunohistochemistry.
Varachev V et al.
Diagnostics (basel, Switzerland), 2024
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
37922692 (PubMed )
Supplement: mmc1.docx
A genetic model for central chondrosarcoma evolution correlates with patient outcome.
Cross W et al.
Genome Medicine, 2022
36042521 (PubMed )
Supplement: 13073_2022_1084_MOESM3_ESM.docx
Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.
Vuong HG et al.
Cancer Medicine, 2021
IDH1 Non-Canonical Mutations and Survival in Patients with Glioma.
Franceschi E et al.
Diagnostics (basel, Switzerland), 2021
Infratentorial IDH-mutant astrocytoma is a distinct subtype.
Banan R et al.
Acta Neuropathologica, 2020
Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma.
Zhu GG et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS et al.
Neuro-oncology, 2016
Select a paper to view details